Business
KRTL Biotech Showcases Gastrointestinal Health Portfolio to Address Global Demand for Accessible Digestive Care
KRTL Biotech Showcases Gastrointestinal Health Portfolio to Address Global Demand for Accessible Digestive Care.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL\r\nHolding Group Inc. (OTC: KRTL) (\"KRTL Holding\" or the\r\n\"Company\") today announced that its majority-owned subsidiary, KRTL\r\nBiotech, Inc., is highlighting its international Gastrointestinal (GI) Care\r\nproduct line, which includes a range of formulations addressing digestive\r\ndiscomfort, acid-related disorders, and hydration needs across diverse patient\r\npopulations.\r\nThe\r\nproduct line—developed and manufactured in collaboration with Industria\r\nQuímico-Farmacéutica SIGMA Corp.—includes antacids, proton pump inhibitors,\r\nantidiarrheals, antiemetics, and oral rehydration therapies, all designed to\r\nmeet the clinical and practical needs of pharmacies, public health systems, and\r\nhospital networks.\r\n\"Digestive\r\ncare is a daily necessity for patients and providers alike,\" said Daniel\r\nBishop, CEO of KRTL Biotech. \"Our GI portfolio addresses everything from\r\nminor discomfort to acute dehydration, and these products are positioned for\r\nregional and global impact.\"\r\nKey\r\nformulations include:\r\n\r\n Omeprazole\r\n and Pantoprazole (acid reflux and GERD)\r\n Aluminum\r\n hydroxide + magnesium combinations (antacid suspensions)\r\n Loperamide\r\n and Racecadotril (antidiarrheals)\r\n Simethicone\r\n and dimethicone (gas and bloating relief)\r\n Electrolyte\r\n powders and oral hydration salts (rehydration)\r\n Domperidone\r\n and metoclopramide (motility and nausea)\r\n\r\nThese\r\nproducts are manufactured under GMP-certified standards in Bolivia and are\r\nwidely used across Latin America through both private and public channels.\r\nSeveral of these medications are included in national essential medicines lists\r\nand serve critical functions in pediatric, adult, and geriatric care.\r\n\"From\r\npharmacies to emergency rooms, gastrointestinal therapies are essential in\r\nevery healthcare environment,\" said Patricia Wilstermann, CEO of SIGMA.\r\n\"We’ve built this line with both clinical consistency and broad\r\naccessibility in mind.\"\r\nKRTL\r\nBiotech is currently reviewing potential U.S. and international regulatory\r\ndesignations for select GI products, including OTC Monograph eligibility and\r\nANDA filings for prescription formulations. Certain hydration and antacid\r\nproducts may be prioritized for near-term export consideration due to their\r\nalignment with OTC use cases....